Given B203
89 Beaumont Ave
Burlington, VT 05405
United States
Pediatrics and Biochemistry
BIO
I received my M.D from the State University of New York at Stony Brook in 2005. I went on to complete my residency in pediatrics, and served as chief resident of pediatrics, at Albany Medical Center. I spent the next six years at Duke University, as a fellow, chief fellow, and then medical instructor in Pediatric Hematology-Oncology. During this time, I trained in the laboratory of Dr. Dan Wechsler, studying altered iron biology in CALM-AF10 transformed leukemia.
As a clinical pediatric hematologist-oncologist, I have a deep appreciation for the unsolved problems in the field of pediatric cancer. I bring those questions back to the lab, and try to understand them from a cellular and molecular standpoint, with the ultimate goal of developing novel, targeted therapies. My primary interest is in high risk pediatric leukemia, with a focus on leukemias that carry the CALM-AF10 chromosomal translocation. There are several projects ongoing in the lab, looking at mechanisms of leukemogenesis and chemotherapy resistance in these leukemias. We are particularly interested in the bidirectional interaction between leukemia cells and components of the bone marrow microenvironment, specifically the ways in which these interactions are altered by the CALM-AF10 fusion oncoprotein. Through our early investigations, we have identified novel targets for therapy, and are testing these targeted therapies in combination with traditional chemotherapy in vitro.
Publications
Area(s) of expertise
Pediatric Leukemias: epigenetics, mechanisms of leukemogenesis, and novel treatment development
Bio
I received my M.D from the State University of New York at Stony Brook in 2005. I went on to complete my residency in pediatrics, and served as chief resident of pediatrics, at Albany Medical Center. I spent the next six years at Duke University, as a fellow, chief fellow, and then medical instructor in Pediatric Hematology-Oncology. During this time, I trained in the laboratory of Dr. Dan Wechsler, studying altered iron biology in CALM-AF10 transformed leukemia.
As a clinical pediatric hematologist-oncologist, I have a deep appreciation for the unsolved problems in the field of pediatric cancer. I bring those questions back to the lab, and try to understand them from a cellular and molecular standpoint, with the ultimate goal of developing novel, targeted therapies. My primary interest is in high risk pediatric leukemia, with a focus on leukemias that carry the CALM-AF10 chromosomal translocation. There are several projects ongoing in the lab, looking at mechanisms of leukemogenesis and chemotherapy resistance in these leukemias. We are particularly interested in the bidirectional interaction between leukemia cells and components of the bone marrow microenvironment, specifically the ways in which these interactions are altered by the CALM-AF10 fusion oncoprotein. Through our early investigations, we have identified novel targets for therapy, and are testing these targeted therapies in combination with traditional chemotherapy in vitro.
Publications
Areas of Expertise
Pediatric Leukemias: epigenetics, mechanisms of leukemogenesis, and novel treatment development